Cell, Molecular and Developmental Biology Program Graduate School of Biomedical Sciences, Tufts University, Boston, MA 02111, USA.
Department of Chemistry, Tufts University, Medford, MA 02155, USA.
Chembiochem. 2020 Oct 1;21(19):2777-2785. doi: 10.1002/cbic.202000212. Epub 2020 Jun 22.
A growing body of evidence suggests that autophagy inhibition enhances the effectiveness of chemotherapy, especially in difficult-to-treat cancers. Existing autophagy inhibitors are primarily lysosomotropic agents. More specific autophagy inhibitors are highly sought-after. The microtubule-associated protein 1A/1B light chain 3B protein, LC3B, is an adapter protein that mediates key protein-protein interactions at several points in autophagy pathways. In this work, we used a known peptide ligand as a starting point to develop improved LC3B inhibitors. We obtained structure-activity relationships that quantify the binding contributions of peptide termini, individual charged residues, and hydrophobic interactions. Based on these data, we used artificial amino acids and diversity-oriented stapling to improve affinity and resistance to biological degradation, while maintaining or improving LC3B affinity and selectivity. These peptides represent the highest-affinity LC3B-selective ligands reported to date, and they will be useful tools for further elucidation of LC3B's role in autophagy and in cancer.
越来越多的证据表明,自噬抑制可以增强化疗的效果,特别是在治疗困难的癌症方面。现有的自噬抑制剂主要是溶酶体靶向剂。人们非常希望能有更特异的自噬抑制剂。微管相关蛋白 1A/1B 轻链 3B 蛋白(LC3B)是一种衔接蛋白,在自噬途径的几个关键点上介导关键的蛋白-蛋白相互作用。在这项工作中,我们使用已知的肽配体作为起点,开发了改进的 LC3B 抑制剂。我们获得了结构活性关系,量化了肽末端、单个带电残基和疏水性相互作用的结合贡献。基于这些数据,我们使用人工氨基酸和多样性导向的订书钉技术来提高亲和力和对生物降解的抗性,同时保持或提高 LC3B 的亲和力和选择性。这些肽代表了迄今为止报道的最高亲和力的 LC3B 选择性配体,它们将是进一步阐明 LC3B 在自噬和癌症中的作用的有用工具。